Actavis To Exit China As Unfriendly Government Not Worth It

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Actavis Plc (ACT:US), the second-biggest generic drugmaker by market capitalization, said it will end its presence in China because of the difficult business climate.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC